Advertisement

Topics

Lundbeck Pharma A/S Company Profile

12:34 EDT 19th June 2018 | BioPortfolio

Nil

Location

Dalbergstrøget 5
Taastrup
2630
Austria

Contact

Phone: 43 71 42 70
Fax: 43 71 42 74
Email: pharmainfo@lundbeck.com


News Articles [782 Associated News Articles listed on BioPortfolio]

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful.  Danish pharma Lundbeck has decided to ...

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will p...

Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback

Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by...   

Lundbeck to buy Prexton Therapeutics in EUR905m deal

Danish pharma company H. Lundbeck has agreed to acquire Switzerland-based Prexton Therapeutics, which develops drugs for Parkinson's disease and other brain disorders, in a deal worth about DKK6.75bn ...

H. Lundbeck A/S: Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

-- Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones -- Foliglurax is a first-in-class t...

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Valby, Denmark, 2018-03-20 14:01 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Dir...

Lundbeck takes risk on Parkinson’s treatment, €905m on table

CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take a calculated risk on Prexton Therapeutics and its sole candidate for P...

Lundbeck bulks up neuro pipeline with Prexton buy

As part of the deal, Lundbeck will add a first-in-class small-molecule compound, foliglurax, to its growing CNS repertoire.

Drugs and Medications [253 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Moving pharma contracting into the era of accountability.

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

Rejuvenating the Face: An Analysis of 100 Absorbable Suture Suspension Patients.

Absorbable suture suspension (Silhouette InstaLift, Sinclair Pharma, Irvine, CA) is a novel, minimally invasive system that utilizes a specially manufactured synthetic suture to help address the issue...

Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder.

Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transu...

A totally new system is needed for drug research and development.

In response to my paper, where I call for abolishment of patents and for drug research and development as a public enterprise, Raj asserts that there is an increase in novel drug discoveries. The fact...

Clinical Trials [80 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Companies [759 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

LifeCycle Pharma

LifeCycle Pharma was founded in June 2002 as a spin-off from H. Lundbeck A/S. Its investors include H. Lundbeck A/S, Novo A/S, Nordic Biotech, Alta Partners (USA), and Adamant Biomedical Investments (...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...

Lundbeck Pharma A/S

Nil

Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...

More Information about "Lundbeck Pharma A/S" on BioPortfolio

We have published hundreds of Lundbeck Pharma A/S news stories on BioPortfolio along with dozens of Lundbeck Pharma A/S Clinical Trials and PubMed Articles about Lundbeck Pharma A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Pharma A/S Companies in our database. You can also find out about relevant Lundbeck Pharma A/S Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record